Move over Appen: A new artificial intelligence stock to list on the ASX

This technology could save some of the 9 million lives lost each year to coronary artery disease.

| More on:
A medical specialist holds a red heart connected via technology and artificial intelligence (AI)

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Appen Ltd (ASX: APX) is the most prominent technology company on the ASX involved in artificial intelligence (AI).

Its shareholders have suffered immensely in recent times, with the stock dropping more than 65% over the past 12 months. But even with that calamity, Appen shares have quadrupled in the last 5 years.

And it has gained more than 1,668% since listing in January 2015.

So if you're interested in getting in from the ground level on a new AI player, there is one such company listing this month on the ASX.

Heart disease will only increase with an ageing population

Perth's Artrya Limited (ASX: AYA) has just closed its initial public offer, with its shares due to commence general trading on the ASX on 26 November.

The company's technology aims to automate the diagnosis of coronary artery heart disease, which can cause heart attacks.

Co-founder and managing director John Barrington said there is growing demand for improved detection of coronary artery disease.

"With 9 million people dying from the disease each year globally, the pressure on health systems is already substantial, and it's only going to increase over the next few decades with ageing populations," he said.

"This float will assist the company in its next stage in expansion."

During the IPO, shares were offered for $1.35 each to raise $40 million and give Artrya a market valuation of $105.45 million.

According to the company, it has received $19 million of funding over the past 2 years from both investors and government research funds.

The Motley Fool has enquired with Artrya to confirm the progress of the IPO.

'No warning signs of a heart attack'

Artrya's flagship cloud software suite is called Salix, which non-invasively detects the presence of "vulnerable plaque" in a patient's arteries in about 15 minutes.

Such plaque is liable to rupture and cause heart attacks.

The technology was developed in conjunction with expertise from the University of Western Australia, the Harry Perkins Institute of Medical Research, and the Ottawa Heart Institute.

An "unrestricted launch" across Australia is scheduled for early in the new year while the IPO money will be used to take the technology overseas after that.

"Coronary artery disease affects an estimated 126 million people worldwide," said Artrya chair Bernie Ridgeway.

"Of those, the majority have no warning signs of a heart attack. As the prevalence of CAD rises due to an ageing population, global health systems will have to deal with more CAD cases."

He added that Salix is expected to disrupt the international market for Coronary Computed Tomography Angiography (CCTA) scans and Invasive Coronary Angiogram (ICA) procedures.

"An estimated 20 million cardiac CT scans are expected to be performed in both North America and Europe alone by 2025," said Ridgeway.

"By addressing current limitations in diagnostic reporting for CAD, Salix has a valuable first-mover advantage."

Salix was placed on the Australian Register of Therapeutic Goods (ARTG) as a Class 1 medical device in November last year.

Artrya is pursuing a subscription model for commercialisation of the software.

"This model will help Artrya penetrate the global CCTA and ICA markets because healthcare providers pay no upfront costs to use Salix," Ridegeway said.

"Artrya believes the software-as-a-service model could deliver annuity revenue and profitable margins for the company."

Motley Fool contributor Tony Yoo owns shares of Appen Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Appen Ltd. The Motley Fool Australia owns shares of and has recommended Appen Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Technology Shares

A man sits in casual clothes in front of a computer amid graphic images of data superimposed on the image, as though he is engaged in IT or hacking activities.
Technology Shares

2 ASX tech stocks to buy during an anticipated 15% to 20% sector pullback in 2025

Expert reveals 2 of his favourite tech stocks and at what prices we should buy them during a dip.

Read more »

A man leans forward over his phone in his hands with a satisfied smirk on his face although he has just learned something pleasing or received some satisfying news.
Technology Shares

Life360 shares: A generational opportunity to get rich?

I think the Life360 share price could more than double again in the year ahead.

Read more »

a woman sitting at a desk checks an old fashioned calendar resting against her wall as she sits with documents in front of her.
Technology Shares

Own WiseTech shares? You need to know about these dates in 2025

Put these dates in your calendar.

Read more »

a young child wearing a cardigan and thick black glasses places his hand on a nearly rounded object and his hair lifts at right angles to his head thanks to static electricity.
Technology Shares

Up 223% in a year, why this ASX 200 tech stock could keep surging higher in 2025

A leading expert expects the ASX 200 tech company to provide strong 2025 earnings guidance.

Read more »

Man with rocket wings which have flames coming out of them.
Technology Shares

Pro Medicus shares jump to record high on big news

This high-flying stock keeps breaking records. Here's what is happening today.

Read more »

man thinking about whether to invest in bitcoin
Technology Shares

Should you buy WiseTech shares before earnings season?

Is this tech star a buy? Let's see what analysts are saying about it.

Read more »

A woman sits at her home computer with baby on her lap, and the winning ticket in her hand.
Technology Shares

Could this undervalued ASX stock be your ticket to millionaire status?

I reckon this stock is on track to deliver significant growth.

Read more »

Technology Shares

2 of the best ASX 300 stocks to buy now

Bell Potter has named these as best buys. Here's what you need to know.

Read more »